Targeted therapies have been recommended as first‐line treatment in patients with advanced, recurrent, or metastatic ROS1‐positive NSCLC, as well as for EGFR mutations or ALK gene fusions. This evidence concerns the gene ALK and non-small cell lung carcinoma.